Dr. Moore is director of the Bras Family Drug Development Program at Ontario Cancer Institute/Princess Margaret Hospital. This program was selected by the NIH as one of seven north American sites to perform new drug development of novel anti-cancer agents. This has lead to a major expansion of both the laboratory and clinical components of the drug development program.
Areas of focus for new drug development are signal transduction inhibitors, modulation of gene expression and angiogenesis.
Industry Expertise (4)
Areas of Expertise (6)
University of Waterloo: Bachelor of Mathematics, Mathematics and Computer Science 1975
The University of Western Ontario: Doctor of Medicine (M.D.), Medicine 1980
- Ho Chair in Prostate Cancer Research, Princess Margaret Hospital
- Chair of the National Cancer Institute of Canada GI cancer disease site
- Professor, Department of Medicine and Pharmacology, University of Toronto
This phase II, open-label, randomised study evaluated whether patients with metastatic pancreatic cancer receiving erlotinib/gemcitabine derived survival benefits from increasing the erlotinib dose.
A prospective cohort study was conducted to evaluate toxicity, quality of life (QOL), and clinical outcomes in patients treated with intensity modulated radiation therapy (IMRT) and concurrent chemotherapy for anal and perianal cancer.
To evaluate the performance of active surveillance as a management strategy in broad populations and to inform the development of surveillance schedules by individual patient data regarding timing and type of relapse.
The BRCA1/2 proteins are involved in regulation of cellular proliferation by DNA damage repair via homologous recombination. Therefore, BRCA1/2 mutation carriers with pancreatic cancer may have distinct biologic outcomes.
Tremelimumab (CP-675,206) is a fully human monoclonal antibody binding to cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) on T cells that stimulates the immune system by blocking the CTLA4-negative regulatory signal. Combination with standard chemotherapy may strengthen antitumor therapy. This is a phase Ib, multisite, open-label, nonrandomized dose escalation trial evaluating the safety, tolerability, and maximum tolerated dose (MTD) of tremelimumab combined with gemcitabine in patients with metastatic pancreatic cancer.